报价延迟最少15分钟:2026/04/26 01:19 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.5 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.36/-2.60
|
|
企业价值
88.43M
|
| 资产负债 |
|
每股账面净值
4.22
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
25.21M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance itssignature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration. |
